The high-profile hedge fund run by veteran stockpicker Phil King has slashed the value of its stake in Opthea by two-thirds after the eye treatment biotech said it faced collapse after the failure of a key clinical trial.
While the company last traded at 60¢ per share, before it entered an extended pause ahead of the publication of the trial result, Regal Partners told investors it was now valuing Opthea at 20¢ per share.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。